This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Hello, and welcome to the Phantom Pharmaceuticals second quarter 2024 earnings results call. At this time, all participants are on a listen-only mode. After the presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automatic message advising your hand is raised. Please be advised that today's conference is being recorded. With that, I would like to turn the conference over to Eric Chiarelli, Phantom's Head of Risk Relations. Please go ahead.
spk09: Thank you, operator. Hello, everyone, and thank you for joining us this morning to discuss Fathom's second quarter 2024 results. This morning's presentation will include remarks from Terry Curran, our president and CEO, Martin Gilligan, our chief commercial officer, and Molly Henderson, our chief financial officer. Azmi Nabulsi, our chief operating officer, will also be joining the team during the Q&A portion of today's call. Just a couple of logistical items before we get started. Earlier this morning, we issued a press release detailing the results we will be discussing during the call. A copy of that press release can be found under the News Releases section of our corporate website. Further, the recording of today's webcast can be found under the Events and Presentations section of our corporate website. Before we begin, let me remind you that we will be making a number of forward-looking statements throughout today's presentation. These forward-looking statements involve risks and uncertainties, many of which are beyond FASM's control. Actual results can materially differ from the forward-looking statements, and any such risks can materially adversely affect the business, the results of operations, and the trading prices for Fathom's common stock. A discussion of these statements and risk factors is available on the current Safe Harbor slide, as well as in the risk factors section of our most recent Form 10-K and subsequent SEC filings. All forward-looking statements made on this call are based on the beliefs of Fathom as of this date, and Fathom disclaims any obligation to update these statements. With that, I will now turn the call over to Terri Curran, Fathom's President and CEO, to kick us off. Terri?
spk07: Thank you, Eric, and thank you to all those joining us on today's call. Fathom was founded on vision and a set of goals that, from the start, many considered lofty. But over the last five years, we've checked one box after another. We've demonstrated differentiation versus a 30-year-old standard of care earned approvals for broad labels, launched multiple products spanning three indications, and secured favorable commercial coverage in a genericized market. To date, we've accomplished exactly what we set out to do. So whether you're new to the story or have followed us since the start, I encourage you to reflect on our track record as it sets the stage for how we intend to continue delivering on our goals for Vuketna. Today, I'm excited to report specifically on the great progress we made during the second quarter of 2024. The team has been focused on executing our commercial launch strategies with physicians, patients, and payers. In only our second full quarter following launch, we believe the results of these efforts have been impressive and demonstrate strong momentum as we enter the back half of 2024. Before diving into our latest launch metrics, I'd like to provide an update on two major developments, the Quesna's approval for non-erosive GERD and our expanded commercial coverage. As we announced on July 18, the FDA approved the Quesna for the relief of heartburn associated with non-erosive GERD in adults. We're extremely pleased with the strength of the label, which highlighted the Quesna's rapid onset of action and durability of effect. This outcome was a key milestone in our commercialization journey, expanding the total addressable market for the kwisna. GERD conditions impact about 65 million US adults annually, with about 22 million being diagnosed and treated with a prescription medication. Non-erosive GERD alone is responsible for over two-thirds of this population. This impressively large market has demonstrated the need for an alternative treatment option, given the high degree of patient dissatisfaction and inadequate symptom relief. Building upon our previous approval for erosive GERD, this third and largest indication allows Equisner to be considered as a treatment option for all patients suffering from GERD or H. pylori. In anticipation of the Purdue for Action Day, Our existing sales force was pre-trained and prepared to begin promotion in the field immediately upon approval. It is important to note that the non-erosive GERD patient journey and target prescriber base mirrors that of erosive GERD, which allows us to leverage our existing promotional efforts. In fact, over the past two weeks, we've already seen a notable increase in demand for 10 milligram tablets, which is the approved dose for non-erosive GERD. Moreover, we believe the commercial access we have secured thus far also applies to non-erosive GERD patients who are prescribed the Quesna bottles. Given the overlapping commercial dynamics across GERD conditions, our strategy has always been to hit the ground running. With this approval, the Quesna has now cleared another hurdle and is poised to recognize the full GERD market opportunity as we work towards our goal of displacing PPIs. Our recent expansion of commercial coverage will be a key driver in achieving that goal. After announcing our placement on Cigna formularies midway through Q2, we recently announced the addition of the QSNA to CVS Caremark's national formularies. As the country's largest pharmacy benefit manager, responsible for over 26 million commercial lives, this was a major development in ensuring widespread coverage for the QSNA. And later in this call, Martin will provide an update on several other key payers for which we've recently secured formery placement. Our efforts have resulted in an estimated $116 million commercially insured lives now having access to the QSNA. Importantly, across the majority of this coverage, we were successful in securing position on formeries in line with our single step strategy through a generic PPI prescription. We're extremely pleased with this broad commercial coverage we've achieved for the QISNA while still in the early stages of launch. One of the most impressive examples of our launch success has been the evolution of the QISNA volume. I'm pleased to share that launch to date, total demand has now surpassed 122,000 scripts written, of which over 60,000 have been filled by patients. We're remaining energized by these metrics and believe their growth trajectories are a testament to increasing interest from prescribers and expanded availability for patients. Over the last few months, we've continued to see extraordinary testimonials pour in from these physicians and patients alike. Almost daily, we receive positive feedback telling us how Sequesnet is relieving symptoms quickly and improving lives. Pictures of healed erosion, stories of sleeping through the night for the first time in years, And overall quality of life improvements are just some of the anecdotes that have made us proud to be able to offer this first-in-class treatment option to patients suffering from acid-related conditions. And with non-erosive now approved, we're thrilled by the opportunity to provide these benefits to millions more patients in need. In parallel with launch, we continue to explore development opportunities for Vukizna. We're planning to initiate two clinical programs, a Phase III trial for as-needed dosing in non-erosive GERD, and a Phase II trial in eosinophilic esophagitis, or EOE. Both programs aim to leverage the rapid, potent, and durable acid suppression profile of the Quesna. If these programs lead to FDA approvals, we believe these indications will continue to expand that total addressable market and further differentiate the Quesna from PPIs, which are not approved for either indication. On the financial side, Molly will further detail our second quarter 2024 results later in the call for which we reported revenues of $7.3 million and ended with $276 million in cash. We remain confident that our strong balance sheet will enable us to continue delivering on our launch and development strategies. After two full quarters on the market, the Quesna's commercialization journey has progressed extremely well. Each quarter we build upon our previous successes, bringing us closer to achieving the blockbuster opportunity we believe is possible for the Quesna. Today's results are evidence of our preparedness and commitment to delivering critical milestones in a short period of time. We've unlocked the largest segment of the GERD market and enhanced access for millions of patients. I'm looking forward to continuing this journey and seeing Vaquesna's position grow in the marketplace. I'll now turn the call over to Martin to dive deeper into recent commercial updates. Martin.
spk04: Thanks, Teri, and hello, everyone. I'm excited to share further details on the great progress we've made over the last three months. The Vaquesna launch is advancing as anticipated, and we're happy with our latest performance metrics, which I will touch on shortly. And the scope of launch timing We still consider ourselves in the early stages of the journey, and we've already made significant strides at building brand recognition and commercial coverage. I'll share updates on several of our commercial tactics, but allow me to begin with perhaps the clearest indicators of progress, our launch metrics. Today we're reporting our latest available written and filled prescription data as of July 26, which is exactly three months since our previously reported data. Over that period, the number of Voquesna scripts written has grown by more than 180% to over 122,000 prescriptions, while the number of scripts filled has grown by more than 240% to over 60,000 prescriptions. In tandem, the number of prescribers who have written a filled script has now increased to roughly 8,200 as of July 19th. We are pleased to see sustained material growth across all three of these metrics. On a quarterly basis, we observed sequential growth of more than 265%, with the number of filled scripts increasing from 9,500 in Q1 to 35,000 in Q2. As we've clarified in previous quarters, these figures include prescriptions flowing through retail pharmacies, which are captured by Acuvia, as well as those flowing through BlinkRx, one of our patient assistant programs. Of the scripts filled in Q2, approximately 65% were filled through retail pharmacies and captured by Acuvia. Additionally, we are also proud to share the growing number of physicians writing Vaquesna quarterly. At the end of Q2, about 7,250 prescribers had written a filled Vaquesna prescription, which reflects a growth of approximately 150% compared to Q1's cumulative writer count. We've previously called out the specialty mix leaning towards GIs, which continues to hold true. More recently, we have started to observe an increase in nurse practitioners and physician assistants who are important writers in the long-term management of GERD patients. And with the non-erosive label expansion now approved, we believe we will see the specialty mix continue to evolve as primary care physicians consider Bequesna for the millions of patients with acid-related heartburn. Another important development has been the improvement in the conversion rate between total demand and filled request and prescriptions. Since our last earnings report, our launch to date fill rate has increased from 41% to nearly 50%, reflecting the impact of pull through from commercial coverage. We see this as an impressive accomplishment compared to what might typically be expected at this stage of launch. With recent access wins, we believe our fill rate will continue to improve, allowing us to realize more of the revenue potential associated with our total demand. As you heard Terry mention earlier, we have made some terrific advances in securing widespread commercial coverage. This part of our launch strategy, in particular, was often questioned given the complexity of the payer systems and Viqueza's entrance into a genericized market. Skepticism frequently surfaced about whether Voquesna would require evidence of endoscopy to obtain reimbursement or if it would be niche to only severe patients. But today, I'm proud to share that those questions are behind us and we've delivered exactly as we intended. After being placed on formularies at Express Scripts and Cigna earlier this year, Voquesna recently earned formulary placement with several other key payers, including CVS Caremark, UnitedHealthcare, Optum, Aetna, and Prime Therapeutics. Since the end of Q2, we've added about 38 million commercial lives to Bequesna's covered population, bringing the total to an estimated 116 million people, or 77% of all U.S. commercial lives. Not surprisingly, all plans govern utilization management differently. But across the vast majority of covered lives, we believe we have been successful in negotiating access subject to a single step edit to a generic PPI prescription. As a result, Bequesna is now available and affordable to millions of commercially insured patients. Additionally, our access wins were extremely timely as we recently kicked off Bequesna's launch of non-erosive GERD. Since coverage is contracted for the bottle presentation, we believe commercially covered patients with GERD, regardless of type or severity, are now able to easily access Vaquesna. With coverage in place at all three major PBMs and several other large payers, our aim now is to pull through demand via the plans for which Vaquesna is on formulary. Now, this begins with promotion. Immediately following the non-erosive approval, our sales force began sharing the news with physicians. One of our main goals is to inform prescribers that VEQUESNA can now be used for all GERD sufferers with broad commercial coverage in place, providing access to patients. We're simultaneously emphasizing VEQUESNA's rapid, potent, and durable acid suppression profile, which is reinforced by our strong product label. The reps are also communicating promotional messages focused on the key elements of differentiation, such as VEQUESNA's sustained effect with all-day and all-night heartburn relief. Meanwhile, with consumers, the Viquezna Can Kick Some Acid DTC campaign continues to have an impact as it airs across digital channels as well as streaming and broadcast television. Without a doubt, word is spreading about the positive real-world experiences patients are having with Viquezna. With access in place and an expanded label applicable to the entire GERD population, our mission is to ensure as many physicians and patients as possible know about Viquezna and its power to help treat GERD. Over the last three months, we've made significant progress across numerous aspects of launch. We have elevated our promotional efforts, heightened Vukresna brand awareness, increased written and field scripts, expanded commercial access, and unlocked the full GERD market. I want to emphasize that these were foundational elements of our launch plan, and with each in place, we're well-positioned to take advantage of the opportunity that lies ahead. Further, the feedback from these early months of the erosive launch and early weeks of the non-erosive launch has been very strong. In the coming quarters, we will continue to execute with the aim of delivering on the high bar we have set for the Viquezna brand. We are excited by our current momentum and confident in our ability to realize this blockbuster opportunity. I'll now pass it off to Molly to walk through our financial results. Molly?
spk05: Thank you, Martin, and hello to everyone on the call. I'm happy to share our second quarter 2024 financial results with you today. We have made great strides in achieving regulatory and commercial milestones, which have translated into a strong quarter for Fathom. Before going into the numbers, I'd like to note two items. First, during this call and similar to previous calls, we will not be providing financial guidance regarding projected revenues or earnings as we are still in the early quarters of launch. Additionally, I will be commenting on both GAAP and non-GAAP financial measures. Supporting schedules with detailed reconciliations between non-GAAP measures and their most directly comparable GAAP measures will be discussed later in my section and can be found in this morning's press release. Now turning to the numbers. For the second quarter, 2024, we reported net revenues of $7.3 million, which represents a 283% sequential quarterly increase, driven primarily by the increase in sales for PESNA prescriptions. Changes in inventory stocking had a lesser impact this quarter. Following the non-erosive label expansion, we believe there will still be another couple quarters before we have a better sense of steady-state stocking behaviors and their impact. As for gross to net, we observed a discount rate in line with our expectations we set forth at the outset of launch. There were no one-time events impacting GTN this quarter as there were in the first quarter. As a result of recently expanded access with major payers and the non-erosive launch, we believe our GTN discount will continue to evolve over the course of the third quarter and through the end of calendar year 2024. For the quarter ended June 30, 2024, we reported gross profit of $5.9 million, which equates to a gross margin of 81%, a sequential quarterly increase of about 350 basis points. Moving down the P&L to our operating expenses, we reported non-GAAP R&D spend of $6 million for the second quarter ended 2024, which represents a 45% reduction in spend compared to the second quarter of 2023. This also reflects a 26% decrease sequentially compared to last quarter. Both decreases were primarily related to lower clinical trial costs associated with the wind down of activities related to our phase three non-erosive daily dosing trial, which we read out last year. As for SG&A, we reported non-GAAP expenses of $71.1 million for the second quarter of 2024. This represents an increase of about $57.6 million relative to the same period of 2023 and a sequential increase of approximately $13.5 million compared to Q1. Both increases were driven by the continued build-out of our commercial infrastructure and marketing activities in support of the Coquitlam launch. In particular, this period's SG&A expenses include our first full quarter of advertising costs, which approximated $16.7 million, and were primarily related to our ongoing Boquesna can kick some ass DTC media campaign. We do not anticipate a significant increase in spend relative to our DTC campaign for the remainder of 2024. Similar to previous quarters, the most significant reconciling item between GAAP and non-GAAP operating expenses for these periods was non-cash stock-based compensation. Other non-GAAP reconciling items include non-cash interest on our revenue interest financing liability and non-cash interest expense related to amortization of debt discounts. Turning to EPS, we reported a non-GAAP adjusted net loss of $73.3 million for the second quarter of 2024 or $1.25 loss per share compared sequentially to a loss of $64.8 million or $1.11 loss per share for the first quarter of 2024. As of June 30, 2024, cash and cash equivalents were $276 million. Of note, this balance includes the drawdown of $25 million from our debt facility in mid-June. Up to an additional $125 million remains available, of which $25 million is available this year and $100 million is available next year, subject to achievement of certain revenue milestones. We believe we are in a strong financial position to continue supporting the Viquezna launch, which now spans three indications. We remain invested in the long-term growth potential of the brand and reaffirm our expectation that we have cash runway through the end of 2026 based on our current operating plan, expected revenues, and funds available under our term loan. After two full quarters of launch, we are pleased with our financial results. Heading into the back half of 2024, we remain focused on ensuring our teams have the resources needed to maximize the book-wes and opportunity. We believe our key payer wins will translate to a proportional increase in script filled through the retail channel, where revenue contributions are most significant, thereby driving top line growth into year end. With that, I will now turn the call back over to Terri for closing comments. Terri?
spk07: Thank you, Molly. And thank you again to everyone joining us on today's call. In wrapping up today's call, I want to reiterate three numbers. 122,000 prescriptions written. 60,000 prescriptions filled, 8,200 cumulative riders, all of which we achieved in just under eight months since launch, and mostly without broad access or an expanded label. And now, having secured 77% commercial coverage, consider what Bequesna can achieve as a new GERD treatment option proven to help relieve heartburn. We believe the key building blocks are in place for Fathom to realize the Quezada's potential peak revenue opportunity of greater than $3 billion. And I believe the numerous accomplishments we've covered today support an acceleration in our adoption trends. We've stayed true to our strategy, even achieving certain milestones ahead of schedule or with better than expected outcomes. In the upcoming quarters, we will continue to drive value through commercial execution, and we look forward to further improving the lives of patients suffering from acid-related conditions. Thank you again for joining us today. We appreciate your continued interest and support. I'll now turn it over to the operator to facilitate a 10-minute question and answer session. Operator.
spk01: Thank you. Ladies and gentlemen, to ask a question, you will need to press star 1-1 on your telephone and wait for your name to be announced. To withdraw your questions, simply press star 11 again. Please stand by while we compile the Q&A roster. Now, first question coming from the line of Annabelle Samimi with Steve Paul. Your line is open.
spk06: Hi. Thanks for taking my question. Congratulations on all the progress. Just wanted to talk a little bit about the NERD expansion opportunity. I guess one of the things I'm curious is to what extent you need to really start tapping the primary care market to gain access to those patients. I, you know, just from conversations we've had with GIs, the GIs are very familiar with the product. The CCCs are less familiar. And that's where the drug they claim would be pretty revolutionary. So just try to understand what your efforts are going to be over there. And then the second question I have is, you know, in terms of the access that you have for the access you have right now, do you have a sense of the various different types of plans and what percent are more open access plans versus very restrictive plans? Or is the access that you have much broader? then, you know, is it just broader? Like, can you just help us sort of qualify or, you know, characterize some of the plan, the formularies within the plan? Thanks.
spk04: Hey, Annabelle, it's Martin. I got your question in two parts. First, I'll take the NERD expansion. And if I summarize it correctly, you're asking about tapping into primary care physicians. So I would agree with you that GIs have a much higher awareness of Loquesna. than primary care physicians, but that doesn't mean primary care physicians don't have any awareness. If you recall, you know, as we launched back in January, we very much focused on the top decile physicians. That's where we went first and had our highest frequency, and they were mostly gastroenterologists. But I do think what we do know is that we're not starting at ground zero. With the primary care physicians, we're going to be calling on the same physicians, as Terry mentioned earlier, that we called on before. And the patients have the same journey with the same symptoms. And the level of unmet need is equally as high. And we know that patients are actually searching for a new mechanism as well as primary care welcome the opportunity for that. So we've got the momentum going. We've been reaching out to primary care. Obviously, we'll be dialing that up as we're moving forward. And then I'll also mention the direct-to-consumer is going to play a really big role in that. We already know from doing some work, when we went to physicians who prescribed, 25% of them had already said that they've been contacted by their patient who specifically requested Boquesna. And 80% of those physicians granted that request. And that's exactly what we communicated that our expectation was going forward. And those patients are already going to primary care. So we feel really good about our trajectory heading into primary care. I'll switch now to your access. So, listen, here's what I like to say about our access. Numbers are great, 115 million lives, 77% commercial coverage, but it's really the quality of the coverage that truly, really counts. And it's completely aligned with our strategy of one step through a PPI. And I'll just say I think we've done a tremendous job. Obviously, each PBM and payer is comprised of multiple plans and multiple formularies. But we've contracted for one step as the key criteria, ExpressTrip, Cigna, Prime, Therapeutics, CVS Caremark, Aetna, UnitedHealthcare. So our expectation is that a patient will have completed an experience with one PPI and have the opportunity to go on Bequezna.
spk06: Great. Thanks for the call.
spk01: Thank you. And our next question coming from the lineup. Joseph Stringer with Needham & Company, Yolanda Southman.
spk12: Hi, good morning. Thanks for taking our questions. You mentioned that you can leverage the existing Salesforce for the NERD launch here. I guess, when do you anticipate we'll see an impact in the IQ via TRX data, number one? And then number two, maybe as a follow-up to the previous question, It's on the NERD approval and the impact on insurance coverage. You mentioned, of course, 77% of commercial lives covered. What percentage of that is for the bottle? And you mentioned that you anticipate this coverage would carry over to the NERD indication. But I guess, is there any scenario in which that wouldn't be the case, meaning the coverage is, say, for erosive GERD, but it would not be for NERD?
spk04: Sure, Joey. So first I'll talk about the Salesforce. Yeah, even we say we're leveraging, we're actually utilizing, and that was part of our vision and our plan. We set up the Salesforce knowing that non-erosive was coming. So our footprint has been in place. We've been calling on these physicians. I think you probably saw specifically the past two weeks, but really last week, a jump in our prescriptions, which we believe is tied to both ends of your question, right? So first, it's clearly a non-erosive launch. Which is what we anticipated we were going to start seeing a jump there So that will continue to grow over time, but we've got all engines running So we've got the DTC running and then as we just you know announced the details of increasing our commercial coverage So they all do kind of go together and they're working in tandem in terms of the the coverage what we're communicating is that is the coverage for the bottle correct so 77% commercial coverage and And it's our belief that that coverage is also for coverage for the all indications. So all of our contracts where we have one step through a PPI indicate Boquesna for as it's indicated. And we've obviously informed all of the payers of our approval, and we continue to move forward.
spk12: Great. Thanks so much for taking our questions.
spk01: Thank you. And our next question coming from the lineup, Yatin Sinejov with Guggenheim. Yelin, it's open.
spk08: Hey, guys. Congrats on a very good quarter. Just a couple questions for me. Number one on gross to net, could you maybe help us understand where you are in terms of the net yielded? I think my math suggests that it is maybe close to 40% net yield for the quarter. If you can confirm or deny, you know, how close we are to that number and how will that evolve? Should we expect an improvement in the yield? Or because of the NARD indication, there should be sort of reduction in that yield. So that's just first question.
spk05: Sure. Hi, Jan. So yeah, GTN is playing out also as we had expected going into launch. I think the numbers that you're estimating are right within the range that we estimated and not inconsistent with what we see as well. As far as going forward with the improved access that we've recently won, we continue to expect to see a building on that GTN. But like I said, going into launch, we continue to believe it'll be in that 50 to 65% discount on a steady state basis.
spk08: And that's just the retail part, right? Not the horizontal blend ratio that you're employing?
spk05: That's right. That's retail.
spk08: Okay, very good. And then with regard to the NERD sort of uptake, I mean, could you maybe talk about like what will be an average duration of treatment for NERD and how that compared to EE and also if you can articulate what you are seeing in terms of the refill rate. Are patients getting refill and at what frequency? Thank you.
spk04: So, Yann, I had commented earlier that the patient journey is very similar between erosive and non-erosive patient. And it goes beyond similarities. Things are almost spot on. What we know from PPI utilization is that on average, on an annual basis, it's about 150 to 160 days for both indications. So again, it's very similar. So I think we've been communicating that 160 day per year number. And then in terms of refills, we're tracking exactly as you would expect for a successful launch. Right now we're at about 50% new prescriptions, 50% refills, but we expect a lot of fluctuation in that as we now enter non-erosive and new patients are starting to come on board as DTC is running. So there's going to be a lot of fluctuation in that in the coming months. But right now we're right on track where we should be for a successful launch.
spk08: Thank you.
spk01: Thank you. And our next question coming from the line of Umar Rafat with Evercore ISI. Your line is open.
spk10: Hi, good morning. This is from Umar. Thanks for taking our questions. I guess firstly, on NERD launch, how many of the scripts are from the 2Q number? And secondly, on the inventory level, I think last quarter you commented there about two to three weeks of inventory. Has the number changed in the second quarter?
spk05: Yeah, I think we caught a little bit of that. I think the last part was on inventory, so I'll cover that first and maybe repeat the first question after that. But as it relates to inventory stocking, we're still early in launch, but what we're seeing is around two weeks, which is consistent with where we were at the end of the first quarter. So we're not seeing a significant impact on the revenues per se relative to stocking. It's more driven by demand. And then if you could repeat the first question, that would be helpful.
spk10: Oh, yeah. The first one is on NERD launch. How many of the scripts are we seeing from the number reported for the second quarter?
spk04: So, Umar, we had a little bit of a hard time hearing you, but if your question is about the number of scripts for the non-erosive launch, it's just really early to tell that. We're just weeks into this. I think what you can clearly say is, you know, much of the growth that we've seen over the past couple of weeks is probably tied to that. Again, we also have the addition of access and consumer running. But we would expect going forward that those three things will really be key drivers, which is the approval of non-erosive, the growth in commercial access, and then the running of DTC. But right now, you know, we wouldn't have the data to answer that question specifically.
spk01: Thank you. Thank you. Our next question coming from the line of Paul Choi with Goldman Sachs. Your line is open.
spk02: Hi. Good morning, team, and congrats on all the progress. My first question is for Martin, and can you maybe just clarify or elaborate on your prioritization of the nurse practitioners and nursing assistants in the primary care channel just as a driver of the NERD indication and opportunity? versus the GI specialist and just kind of how much of your Salesforce effort is going to be directed there. And my second question is for Molly, which is regarding the access to the additional capital under the Hercules Agreement. Can you just remind me what the criteria and the triggers are for accessing it at this point and sort of how you're thinking about the planning and timing relative to your current burn rate? Thank you very much for taking our questions.
spk04: I'll go first, Paul. Yeah, you hit on the magic category of nurse practitioner or physician assistant. They play a really big role, and they played a big role in erosive third, but specifically in non-erosive. They are the folks who are first-line diagnosed and making treatment decisions. And in primary care, they'll play a really important role. So our sales force definitely spends time with them. Gastroenterologists will always remain to be important. They're high volume physicians. They're influential in the category. But definitely, as you said, we've seen a growth amongst those NPs and PAs. And we expect to see that going forward.
spk05: And then as it relates to, Paul, your question on the debt triggers, we expect that I think, as I mentioned in my prepared remarks, there's 25 million remaining available this year under the next tranche. That is unencumbered, meaning that we have free access to pull that down at our discretion. There's another 100 million that we have available under the facility that has two triggers next year, and those are based upon revenue milestones. But as we continue to reiterate that, we feel we have very good cash position in that we have runway through the end of 2026, and that does assume a drawdown of those debt facilities. And I think one other point I'll make relative to our spend is another comment in my prepared remarks mentioned our DTC spend. We know that's something that often fluctuates through launches, but we feel good with our current amount of spend, and as Martin has indicated, the resources we have in place really help drive the non-erosive launch, we don't expect a significant increase in OPEX spend relative to our commercial activities.
spk02: Great. Thanks for the additional call, Molly.
spk01: Thank you. And our next question coming from the line up, Jason Nickerbacher with Crick. Hello, Amy. The line is open.
spk00: Good morning. Thanks for taking the questions and congrats on the continued progress. Just first for me, and I'm sorry I joined late here, and I might make you repeat yourself, but on the Caremark contract, can you just update me on a little bit more of the details there? Does this also include an OTC attestation for the step-through?
spk04: Yeah, so in terms of Caremark, it's like the others that I described. It's one step through a PPI, and it does not include that OTC attestation, but I want to flag something here. When we came out of the gates with Express Scripts and Cigna, That was beyond even our strategy or what we thought the best case could be. So I just caution you, you know, don't take that as an opportunity loss, that it's not with CVS Caremark. It's really that that was just above and beyond for the other. So we're right on strategy with that one step through a prescription PPI.
spk00: No, it makes sense. And kind of asking the question in the light of You know, that being, you know, kind of an upside case to your previous expectations of that, you know, 77% of covered lives now from commercial patients in the United States that we have, you know, under contract. What portion of that does include that OTC attestation? And then second, just kind of, you know, previously we've discussed kind of street expectations to kind of orient people on how you're thinking about the year. um, you know, as we talk to GIs, which are still the majority of your, of your writers here, at least to my knowledge, um, they definitely speak to, you know, kind of a multiple of, of, of prescriptions that they would expect for NERD patients relative to erosive, um, kind of speak to, you know, your confidence and kind of back half numbers with, again, as it sits today, it's a 50% increase kind of from Q2 to Q3 with kind of that in mind. Thanks.
spk04: Yeah. So a couple parts to your question. Um, In terms of what percent of the access would also have that OTC attestation, I'm just going to say roughly, and I'm going off memory, Jason, out of the 115 million lives, about maybe 22 million of them fall under Express Scripts. So I think that answers the first part. In terms of the second part, I think your question was really about the fill rate. Is that correct moving forward?
spk00: Yeah, more so just on kind of the increased demand that we'll drive from NERD. I mean, in some of our checks, we hear, you know, kind of multiples of prescriptions that they'll write for NERD relative to erosive with your current writers, and then kind of informing how you guys are thinking about kind of street expectations in the second half, where you've kind of oriented people on before. It calls for a 50% increase sequentially into Q3, and just speak to your confidence in that number. Thanks. Yep.
spk04: Yeah, so I'll take, I'll take the first part of that and then pass it off to Molly. So, you know, one of the things that, you know, we've been talking to all of you about for a number of years now is that non-erosive was really the biggest indication. It's three times larger than erosive. So we really just opened up the entire GERD market. And I think our opportunity there is the fact that we have a real differentiated product. You know, it works all day and all night, but also it works very quickly. In our label, it talks about full effect at day two, which is something that a PPI would not have, and then also continues that same effect for both the four-week period as well as the 20-week extension. So it's really got the sustainability, so it's differentiated. And I can tell you, going back to Paul's earlier question, all physicians recognize that. They're seeing the experience, but as Paul brought up, those nurse practitioners and physician assistants, they are just welcoming this product. So we think that non-erosive is exactly as we set out to do. It's just a really large opportunity.
spk05: Yeah, and as it relates to guidance, as you know, we're not providing specific guidance on a quarterly basis, but going into launch, we always knew the back half of 2024 was going to be significant between further access, DTC campaign up and running, and non-erosive label. So those three items are really what's going to drive us home for the rest of this year, and we continue to reiterate that we feel comfortable with a full year consensus of where it is now.
spk03: Great. Thanks, guys, and congrats again.
spk01: Thanks, Chase. Thank you. And our last question coming from the line of Matthew Cuthbert with HCWIN, right?
spk11: Hi, thank you. Good morning, guys. Just quickly here, so for the prescription mix currently favoring GIs, is that more a factor of those patients already having progressed to seeing a GI specialist, at least at this stage, or are primary care physicians at all less receptive to prior authorizations and then patients are essentially being passed forward to GI specialists? Is there any further distinctions there kind of for that mix?
spk04: Yeah, so actually let me, I might mix your different topics here just to clarify. First of all, I think the high utilization of GI is obviously one specialist adopts new products sooner, new mechanisms sooner. But also, and I think I referenced this earlier, out of the gates, we really focus on the highest SL physicians for Rosep GERD, and they were naturally gastroenterologists. So I think you should look at it more of where we put both our reach and our frequency in the early months of launch. Do not interpret that as primary care. Do not see the opportunity or this differentiated product for primary care. And the other thing I'll just say is, just to clarify the PA, for that one step through a PPI, the only thing the physician really needs to do is identify that that patient has been on a PPI So, there's different levels of prior authorizations, and many of them are actually picked right up at the pharmacy, so the physician has no action. So, I'm not sure the primary care actually has that much work to do to get Boquesta.
spk03: Okay, very helpful. I appreciate it.
spk01: Thank you. And that's all the time we have for our Q&A session. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation, and you may now disconnect.
Disclaimer